Earnings

Arcus Biosciences Announces A Clinical Supply Agreement With AVEO Oncology To Evaluate Casdatifan; Agreement Supports A New Randomized Cohort Within The ARC-20 Study Evaluating Investigational Casdatifan Plus Tivozanib Versus Tivozanib Alone In Patients Who Received Prior HIF-2α-inhibitor Therapy; Enrollment Expected To Begin In Q4 2026

Jul 22, 2026 · 04:48 PM ET· updated 2h ago

This agreement supports a new randomized cohort within the ARC-20 study evaluating investigational casdatifan plus tivozanib versus tivozanib alone in patients who received prior HIF-2α-inhibitor therapyEnrollment is

Why It Matters

Arcus Biosciences partnered with another company to test whether combining two cancer medicines works better than one alone. This shows the company is moving forward with research, which is a sign they believe in their medicine.

This read is generated by AI from raw market data and is for education only. It is not financial advice, not a signal, and not a recommendation to buy or sell.

Tickers in Play

RCUS29.95

+0.46 (+1.58%)

Last session drawn · prints held ~15 minutes · licensed exchange data

Source: Benzinga · Read the original report at the publisher. Headline and figures shown for context; data may be delayed.

Disclosure: Educational and informational purposes only — not financial advice. We educate, not advise. Market data may be delayed up to 15 minutes unless marked real-time. Past performance is not indicative of future results.